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Abstract
Background: Cardiac output is a prognostic marker in patients with pulmonary hypertension. Pulmonary blood flow as a
surrogate for cardiac output can be measured non-invasively by inert gas rebreathing. We hypothesized that pulmonary blood
flow can predict outcome in patients with pulmonary hypertension.
Methods: From January 2009 to January 2012, we measured pulmonary blood flow by inert gas rebreathing in outpatients with
pulmonary hypertension. Patients with pulmonary hypertension confirmed by right heart catheterization and a valid inert gas
rebreathing maneuver were followed until January 2016. The investigated outcome was all-cause mortality.
Results: We included 259 patients (mean age 65 13 years, 53% female) with pulmonary hypertension and classified into groups 1
(n¼ 103), 2 (n¼ 26), 3 (n¼ 80), and 4 (n¼ 50) according to the current pulmonary hypertension classification system. The median
time between pulmonary hypertension diagnosis and inert gas rebreathing was 9 (IQR 0; 36) months. During a median follow-up
time of 51 (IQR 20; 68) months, 109 patients (42%) died. Parameters significantly associated with survival (in order of decreasing
statistical strength) were diffusion capacity of the lung for carbon monoxide (DLCO), 6-minute walk distance (6-MWD), age,
NTpro-BNP, WHO functional class, group 3 pulmonary hypertension, and tricuspid annular plane systolic excursion (TAPSE), while
baseline hemodynamics and pulmonary blood flow were not. In multivariable Cox regression analysis, DLCO, age, 6-MWD, and
TAPSE remained significant and independent predictors of the outcome. DLCO as the strongest parameter also significantly
predicted survival in aetiological subgroups except for group 4.
Conclusions: DLCO is a strong and independent predictor for survival in patients with pulmonary hypertension of different
aetiologies, while pulmonary blood flow measured by inert gas rebreathing is not.
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Introduction
Pulmonary hypertension (PH) is characterized by increased
blood pressure in the pulmonary arteries and can be classi-
ﬁed, according to aetiology, into ﬁve groups.1 Pulmonary
arterial hypertension (PAH), group 1 of the current PH
classiﬁcation system, is a rare disease with a limited prog-
nosis even if it improved since ‘‘targeted’’ medication is
available.2 PH due to left heart disease (group 2), lung dis-
ease (group 3), or chronic thromboembolic PH (group 4) is
much more frequent than PAH and also associated with
increased mortality rates.3
Diﬀerent parameters have been used separately or in
combination to predict the prognosis of PH patients.2,4
Clinical parameters like the World Health Organization
Functional Class (WHO-FC) can predict survival both at
diagnosis and follow-up (on speciﬁc treatment).5 Imaging
of the heart by echocardiography including the contractile
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reserve during exercise has been shown to be an independent
prognostic marker in patients with severe PH.6 Prognostic
value has also been identiﬁed for some parameters of car-
diac magnetic resonance imaging.7 The 6-minute walking dis-
tance (6-MWD) provides prognostic information, and adding
peripheral oxygen saturation measurements and heart rate
response might improve its prognostic relevance.8–10 Also,
several variables determined by cardiopulmonary exercise
testing provide prognostic information.11 Levels of natriuretic
peptides (BNP, NTpro-BNP) provide prognostic information
at the time of diagnosis and during follow-up assessments.12
Haemodynamics assessed by right heart catheter (RHC) pro-
vides important prognostic information, both at the time of
diagnosis and during follow-up. Right atrial pressure, cardiac
output (CO), and mixed venous oxygen saturation are the
most robust indicators of right ventricular function and prog-
nosis, whereas mean pulmonary arterial pressure provides
little prognostic information.13 Even if RHC is a safe proced-
ure in experienced hands,14 it remains a time-consuming and
invasive method precluding its use as a frequent follow-up
examination in PH patients. Therefore, other methods to
measure CO have been developed. The inert gas rebreathing
(IGR) method is a non-invasive technique of CO assessment
with good agreement compared to the thermodilution and
the Fick method in RHC examinations, which can be easily
performed in most patients.15,16
The aim of the present study was to assess the prognostic
value of a single CO measurement at rest by the IGR




The present analysis is a single-center study of patients
with European descent and known or suspected PH. From
January 2009 to January 2012, pulmonary blood ﬂow (PBF)
as a surrogate of CO was measured as part of the routine
assessment in consecutive outpatients. Patients with PH
conﬁrmed by RHC and a valid PBF measurement were
followed until January 2016. The investigated outcome
was all-cause mortality.
Data were collected prospectively in patients participat-
ing in an observational clinical study after written informed
consent and retrospectively in the remaining patients. The
protocol of the observational study, the data protection
strategy, and the retrospective data collection and follow-
up of patients were approved by the Ethics Committee of
the University of Regensburg and were in accordance with
the Declaration of Helsinki.
Study population
The PH outpatient clinic of the University Medical Center
Regensburg is a local referral center for patients with known
and suspected PH, following mainly patients with precapil-
lary PH (groups 1, 3, and 4 according to the PH classiﬁcation
system) or PH due to left heart disease (group 2) with signiﬁ-
cant precapillary involvement. Regular outpatient visits are
performed every three to six months in stable patients. At
every visit, blood tests including measurement of NTpro-
BNP, a pulmonary function test including assessment of the
diﬀusion capacity of the lung for carbon monoxide (DLCO),
capillary blood gas analysis, and 6-MWT are conducted. In
addition, WHO-FC, current medication, and adverse events
are recorded in patient’s medical records. An electrocardio-
gram and an echocardiography are performed at least every
second visit, while RHC is performed only if deemed helpful
for clinical decision making (e.g. if clinical worsening is not
clearly attributable to worsening of PH, or before an escal-
ation of targeted PAH medication). In addition, IGR using
the InnocorTM device was routinely performed at every out-
patient visit from January 2009 to January 2012.
All patients with PH conﬁrmed by RHC and a valid PBF
measurement were eligible for participation. In case of more
than one valid PBF measurement, only the ﬁrst one was used.
PH was deﬁned by a mean pulmonary artery pressure of
25mmHg at rest on RHC. Patients were allocated to
groups 1 to 4 of the current PH classiﬁcation system after
thorough diﬀerential diagnosis according to current guidelines.4
Results of examinations mentioned were extracted from the
patient’s medical records at the time of IGR, while the latest
RHC measurement before the IGR was used for description.
Right heart catheter
All patients underwent RHC at rest with determination of
right atrial pressure, pulmonary arterial pressures, and pul-
monary arterial wedge pressure because of suspected PH.
CO was determined by thermodilution. Mixed venous
oxygen saturation was determined from pulmonary artery
blood samples. Pulmonary vascular resistance, cardiac
index, and diastolic pressure gradient were calculated. All
RHC were performed by the same physician.
Pulmonary function tests, DLCO, and PBF measurements
Spirometry and body plethysmography were used to deter-
mine total lung capacity, forced vital capacity (FVC), forced
expiratory volume in the ﬁrst second (FEV1), and their
ratio. DLCO was measured by the single-breath technique
without correction for haemoglobin values or lung volumes.
PBF was measured by IGR using the InnocorTM device
(Innovision ApS, Glamsbjerg, Denmark) as previously
described.15 All measurements were carried out by trained
personnel in a standardized fashion.
Assessment of outcome
All-cause mortality from the time of PBF measurement was
assessed in January 2016 according to medical reports or
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information from the family physician. If patients did not
return for planned follow-up visits, they were contacted by
phone. Patients were censored at last contact, lung trans-
plantation, or pulmonary endarterectomy.
Statistical analysis
Descriptive data are presented as mean (SD) for normally
distributed variables and as median and interquartile
range for not normally distributed variables. Continuous
variables of baseline characteristics were compared by
the t-test and categorical variables by the Chi-square test.
Correlation was tested by the two-sided Pearson test.
Univariate Cox regression analysis was used to analyze the pre-
diction of PBF and other parameters on all-cause mortality.
Signiﬁcant risk factors from the univariable analysis, such as
DLCO, 6-MWD, age, NTpro-BNP, WHO-FC, PH group,
and echocardiographic tricuspid annular plane systolic excur-
sion (TAPSE), were included as covariates in the multivariate
Cox regression. Results are given as hazard ratio estimates
with 95% conﬁdence interval and Chi-square values.
p-Values of <0.05 were considered signiﬁcant. Survival
curves are shown in Kaplan-Meier plots; logrank test was
used to compare estimates of the hazard functions. A Forest
plot was used to visualize hazard ratios of survival for DLCO
in diﬀerent aetiological groups and in the total sample. Data
were analyzed using the SPSS statistical software package
(SPSS 23.0, IBM SPSS Statistics, Armonk, New York, USA).
Results
Patient characteristics
Two hundred ﬁfty-nine consecutive patients (mean age
65 13 years, 53% female) were included from January
2009 to January 2012. Of these, 103 (39.8%), 26 (10.0%),
80 (30.9%), and 50 (19.3%) were allocated to groups 1, 2,
3, and 4 according to the current PH classiﬁcation system,
respectively.1 Patients were predominantly in WHO-FC II or
III, and 157 (60.6%) were on targeted PH medication (phos-
phodiesterase-5-inhibitors, endothelin-receptor-antagonists,
prostacyclin analogues, or riociguat). Median time between
the diagnostic RHC and PBF measurement was nine (IQR 0;
36) months (Table 1). PH groups were signiﬁcantly diﬀerent
according to age (oldest in group 2), 6-MWD (shortest in
group 3), DLCO (lowest in group 3), PBF (lowest in group
1), mean pulmonary artery pressure (highest in group 1),
pulmonary artery wedge pressure (highest in group 2), and
pulmonary vascular resistance (highest in group 1). NTpro-
BNP, TAPSE, and CO (RHC) were similar between groups
(Table 2).
Outcome
During a median follow-up time of 51 (IQR 20; 86) months,
109 patients (42%) died. Patients with PH groups 2 and
3 had the worst prognosis (Fig. 1). The deceased patients
were signiﬁcantly older, had a shorter 6-MWD, higher
NTpro-BNP, lower TAPSE, and worse DLCO (Table 3).
Parameters signiﬁcantly associated with survival (in order
of decreasing statistical strength) were DLCO (2¼ 46.9,
p< 0.001), 6-MWD, age, NTpro-BNP, WHO-FC, group 3
PH, and TAPSE (Table 4). PBF (measured by IGR) and CO
(measured by RHC) were signiﬁcantly correlated (r¼ 0.475,
p< 0.001). PBF as well as CO, pulmonary arterial mean
pressure, and right atrial pressure were no predictors of sur-
vival in the total sample, neither in continuous nor in
dichotomous analyses (every p> 0.05).
In a multivariable Cox regression model including the sig-
niﬁcant predictors of mortality, DLCO, 6-MWD, age, and
TAPSE remained signiﬁcant and independent predictors for
the outcome (Table 4).
If DLCO was adjusted for possible restrictive or obstruct-
ive lung disease (as ratio of DLCO and FVC or FEV1,
respectively), it was still a signiﬁcant predictor of survival
(HR 0.179 (95% CI 0.051; 0.629), 2¼ 56.7, p¼ 0.007 for
FEV1 and HR 0.235 (95% CI 0.0.68; 0.805), 2¼ 54.4,
p¼ 0.021 for FVC, respectively). Dichotomization of
DLCO by its median (49% of predicted) led to a clear
Table 1. Clinical parameters of the 259 analyzed patients.
Patients (n) 259
Age at PBF measurement (years) 65 13
Female sex (n; %) 138 (53%)
WHO-FC 1/2/3/4 (%) 4/40/49/7
6-minute walk distance (m) 344 113
NTpro-BNP (pg/ml) 1620 1940
TAPSE (mm) 18.3 4.9
DLCO (% predicted) 49 22
Mean PA pressure at PH diagnosis (mmHg) 42 11
Cardiac output at PH diagnosis (l/min) 4.9 1.5
Innocor-PBF (l/min) 4.3 1.3
Time between PH diagnosis and
PBF measurement (months)
9 [0; 36]






PH-dual/triple combination therapy (n) 43/6
CCB (n) 47
Anticoagulation 193 (76%)
Note: Results are provided as mean standard deviation for normally distrib-
uted and as median (interquartile range) for non-normally distributed variables.
CCB: calcium channel blocker; DLCO: diffusion capacity of the lung for carbon
monoxide; PA: pulmonary artery; PBF: pulmonary blood flow; PH: pulmonary
hypertension; TAPSE: tricuspid annular plane systolic excursion; WHO-FC:
World Health Organization functional class.
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diﬀerentiation between mortality rates right from the begin-
ning of follow-up (HR 0.267 (95% CI 0.177; 0.404),
p< 0.001; Fig. 2). After three years of follow-up, 87% of
patients with DLCO above the median were alive vs. only
52% of those below the median.
Prognostic factors in different PH groups
DLCO as the strongest parameter also signiﬁcantly pre-
dicted survival in subgroups of patients according to the
PH classiﬁcation system except for group 4 (HR 0.968
Fig. 1. Survival according to pulmonary hypertension aetiological groups.
PH: pulmonary hypertension; PBF: pulmonary blood flow.
Table 2. Clinical and hemodynamic parameters of the 259 analyzed patients differentiated by aetiology.
All patients Group 1 Group 2 Group 3 Group 4 pa
Number 259 103 26 80 50 –
Age (years) 65 13 60 13 70 13 68 10 67 12 <0.001
6-minute-walk distance (m) 344 113 375 112 325 113 302 86 332 128 0.002
Ntpro-BNP (pg/ml) 1620 1940 1447 1825 1661 1236 1631 2026 1948 2292 0.555
TAPSE (mm) 18.3 4.9 18.4 4.6 17.4 4.9 18.3 4.9 18.3 5.5 0.859
DLCO (% pred) 49 22 57 19 54 19 33 18 56 18 <0.001
Mean PAP Dx (mmHg) 42 11 46 12 39 10 37 9 42 9 <0.001
PAWP Dx (mmHg) 10 6 9 4 20 5 9 5 9 4 <0.001
PVR Dx (WU) 7.3 4.3 8.8 5.0 4.1 2.5 6.2 3.2 7.8 3.6 <0.001
CO Dx (l/min) 4.9 1.5 4.8 1.6 5.2 1.7 5.0 1.4 4.9. 1.5 0.608
Innocor-PBF (l/min) 4.3 1.3 4.1 1.3 4.6. 1.4 4.2 1.3 4.4 1.2 0.372
Innocor-PBF (l/min/m2) 2.3 0.6 2.2 0.6 2.6 0.8 2.3 0.6 2.4 0.6 0.033
Note: Results are provided as mean standard deviation.
CO: cardiac output; DLCO: diffusion capacity of the lung for carbon monoxide; Dx: diagnosis; PAP: pulmonary arterial pressure; PAWP:
pulmonary arterial wedge pressure; PBF: pulmonary blood flow; PVR: pulmonary vascular resistance; TAPSE: tricuspid annular plane systolic
excursion; WU: Wood unit.
aDifference between the groups (t-test for continuous variables).
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(95% CI 0.936; 1.001), p¼ 0.059) (Fig. 3). PBF was a sig-
niﬁcant predictor of survival only in patients of PH group 3
(HR 0.753 (95% CI 0.598; 0.949), p¼ 0.016). CO showed
a signiﬁcant predictive value only in patients of group 4 (HR
0.477 (95% CI 0.274; 0.832), p¼ 0.009), mean pulmonary
arterial pressure in groups 2 and 3 (HR 1.067 (95% CI
1.003; 1.135), p¼ 0.040 and HR 1.032 (95% CI 1.002;
1.064), p¼ 0.039, respectively), and right atrial pressure
only in group 4 (HR 1.090 (HR 1.005; 1.182), p¼ 0.036).
Discussion
The present analysis yielded the novel ﬁnding that
DLCO was strongly associated with survival in patients
with PH across diﬀerent aetiologies during a mean follow-
up of 44 months, while PBF measured by IGR was not.
This outcome was independent from other risk factors
signiﬁcantly associated with survival like 6-MWD, age,
NTpro-BNP, WHO-FC (I/II vs. III/IV), PH aetiology
Table 3. Clinical and hemodynamic parameters of the 259 analyzed subjects differentiated by survival status.
Survived Died pa
Number 150 109 –
Age (years) 62 14 69 10 <0.001
6-minute walk distance 373 115 297 92 <0.001
NT pro-BNP (pg/ml) 1250 1792 2121 2027 0.001
TAPSE (mm) 19.0 4.9 17.2 4.7 0.008
DLCO (% predicted) 55 21 41 20 <0.001
Mean PAP at Dx (mmHg) 42 11 42 11 0.946
PAWP Dx (mmHg) 10 6 10 5 0.565
PVR Dx (WU) 7.2 4.3 7.5 4.3 0.620
CO Dx (l/min) 5.0 1.6 4.7 1.4 0.098
Innocor-PBF (l/min) 4.4 1.4 4.1 1.3 0.108
Innocor-PBF (l/min/m2) 2.3 0.6 2.3 0.6 0.556
Time between Dx of PH and PBF measurement 8 [0; 42] 9 [0; 29] 0.020
Note: Results are provided as mean standard deviation.
CO: cardiac output; DLCO: diffusion capacity of the lung for carbon monoxide; Dx: diagnosis; PAP: pulmonary arterial pressure; PAWP:
pulmonary arterial wedge pressure; PBF: pulmonary blood flow; PH: pulmonary hypertension; PVR: pulmonary vascular resistance; TAPSE:
tricuspid annular plane systolic excursion; WU: Wood unit.
aDifference between the groups (t-test for continuous variables).
Table 4. Hazard ratios for mortality in 259 subjects in univariable and multivariable Cox regression analyses.
Univariable analysis Multivariable analysis
HR (95% CI) 2 p HR (95% CI) p
DLCO (% predicted) 0.966 (0.956; 0.976) 46.9 <0.001 0.975 (0.959; 0.991) 0.002
6-minute walk distance 0.994 (0.992; 0.006) 33.0 <0.001 0.996 (0.992; 0.999) 0.014
Age (years) 1.050 (1.030; 1.070) 26.5 <0.001 1.043 (1.009; 1.078) 0.012
NTpro-BNP (pg/ml) 1.000 (1.000; 1.000) 20.0 <0.001 1.000 (1.000; 1.000) 0.410
WHO-FC I/II vs. III/IV 0.498 (0.334; 0.742) 12.2 0.001 1.574 (0.807; 3.072) 0.183
PH group 3 vs. 1/2/4 1.899 (1.290; 2.794) 10.9 0.001 1.262 (0.673; 2.364) 0.468
TAPSE (mm) 0.937 (0.895; 0.981) 7.7 0.005 0.920 (0.859; 0.986) 0.018
PAH-medication y/n 0.762 (0.511; 1.137) 1.8 0.183
Innocor-PBF (l/min) 0.910 (0.786; 1.055) 1.6 0.212
Innocor-PBF (l/min/m2) 0.956 (0.710; 1.286) 0.1 0.765
Note: Shown are the hazard ratios by univariable and multivariable Cox regression analyses and 95% confidence intervals (95% CI).
The variables used in the multivariable regression model were the significant variables from the univariable regression model: DLCO,
6-minute walk distance, age, NTpro-BNP, WHO-FC I/II vs. III/IV, PH group 3 vs. 1/2/4, and TAPSE.
DLCO: diffusion capacity of the lung for carbon monoxide; HR: hazard ratio; PAH: pulmonary arterial hypertension; PBF: pulmonary
blood flow; PH: pulmonary hypertension; TAPSE: tricuspid annular plane systolic excursion; WHO-FC: World Health Organization
functional class.
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(group 3 vs. 1/2/4), and TAPSE. Patients with a DLCO
below the median (49% of predicted value) had a HR of
3.74 (95% CI 2.45; 5.65) (p< 0.001) for all-cause mortality.
Prognostic value of hemodynamic parameters
The invasively measured hemodynamic parameters right
atrial pressure and CO have shown to be robust indicators
of right ventricular function and prognosis in patients
with idiopathic PAH at both diagnosis and follow-up.13
Both parameters had no signiﬁcant prognostic value in
the present analysis, neither in the entire group nor in
the largest subgroup of patients with PAH. This may be
explained by the fact that we assessed survival from the
time of PBF measurement and not from the diagnostic
RHC. Therefore, subsequent targeted therapy could have
Fig. 2. Survival according to diffusion capacity of the lung for carbon monoxide above vs. below median (49% of the predicted).
DLCO: diffusion capacity of the lung for carbon monoxide.
Fig. 3. Forest plot showing hazard ratios of survival for diffusion capacity of the lung for carbon monoxide in different aetiological groups and in
the total sample.
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inﬂuenced this otherwise valid association at least in patients
with PAH.
Use of non-invasive IGR is well established and validated
for assessing CO in the absence of a signiﬁcant intrapulmon-
ary shunt.15 Farina et al. could show that CO can be reliably
measured by IGR in patients with PH.17 However, we were
not able to conﬁrm our hypothesis that a single IGR meas-
urement in outpatients with PH of diﬀerent aetiologies is
prognostically relevant. In patients with PH due to left
heart and lung diseases and chronic thromboembolic PH
(CTEPH), this could be an expected ﬁnding as an associ-
ation between CO and prognosis in these PH groups is not
concisely shown in the literature. However, in patients with
PAH, this ﬁnding is unexpected and may be due to technical
reasons of our measurement. The InnocorTM device meas-
ures arterial oxygen saturation by pulsoxymetry to correct
the measured PBF for possible intrapulmonary shunts, i.e.
the CO is calculated from the PBF plus estimated shunt ﬂow.
However, Farina et al. have shown that the algorithm used
within the InnocorTM device is inaccurate in patients with
PAH and hypoxemia.17 Therefore, we decided to only meas-
ure the PBF as surrogate for CO. However, due to the fact
that PBF is measured by rebreathing, only the blood ﬂow in
ventilated areas (ventilation/perfusion matched) is captured
which leads to a systemic underestimation of CO.18 As
inhomogeneous ventilation/perfusion may vary considerably
even among PAH patients (and maybe due to pulmonary
comorbidities), this could also have inﬂuenced the missing
association between PBF and survival in our patients.
In the present analysis, PBF predicted mortality only in
patients with underlying lung disease. This cannot be
explained by the mechanism discussed above (underestima-
tion of CO by PBF) and may just reﬂect the severity of the
underlying lung disease. Further studies evaluating the
impact of serial PBF measurements on the prognosis of
PH are warranted.
DLCO as prognostic parameter in PH
In the present analysis, among other parameters signiﬁ-
cantly associated with survival (6-MWD, age, NTpro-
BNP, WHO functional class, group 3 PH, and TAPSE),
DLCO was the most powerful one. Some studies reported
on DLCO as a prognostic marker for patients with PH
before. In idiopathic PAH, DLCO is usually normal or
only mildly impaired,19 but patients with a low DLCO
(<45% of predicted value) have a particularly high mortal-
ity.20 Szturmowicz et al. found an increased mortality in
idiopathic PAH patients with an DLCO <55% predicted.21
Kang et al. described a low DLCO as poor prognostic factor
in patients with PAH associated with connective tissue dis-
ease.22 Hoeper et al. found a signiﬁcantly worse survival rate
in patients with PH due to heart failure with preserved ejec-
tion fraction and DLCO <45% predicted.23 Similar ﬁndings
have been reported in patients with chronic lung disease and
PH.24–26 Suda et al. described a decreased DLCO to be
associated with poor outcome in 91 medically treated
CTEPH patients.27 In the present analysis, the DLCO was
at no speciﬁed time during treatment a signiﬁcant predictor
for survival in the entire sample of PH patients and in the
diﬀerent aetiological groups except for CTEPH. This may
be explained by the small sample size of this subgroup,
as the HR is similar compared to the other PH groups
(HR 0.968; CI 95% (0.936; 1.001), p¼ 0.059).
DLCO is inﬂuenced by many factors like the alveolar
capillary volume, the permeability of the alveolar membrane,
the lung perfusion, the haemoglobin concentration, smoking
habits, and potential intrapulmonary or intracardiac shunts.
Regarding this broad spectrum of factors inﬂuencing DLCO,
it is conceivable that its strong prognostic capability is not
only reﬂecting one single pathomechanism. An impaired
DLCO may therefore reﬂect a number of disorders like par-
enchymal lung diseases, obstructive or restrictive ventilatory
abnormalities, heart failure, anemia, smoking, and others,
which are known to have an impact on prognosis and
might exist as underlying cause or comorbidities in PH
patients. Like DLCO, also the 6-MWD has a number of
possible inﬂuencing factors and does not only reﬂect cardiac
function. Interestingly, this parameter was the second most
powerful prognostic parameter in our present analysis.
6-MWD has proven its prognostic value despite of – or just
because of – the quantity of inﬂuencing factors (e.g. age,
cardiac function, ventilatory, orthopedic, frailty, and
others) before.28
The strengths of the present study are the large sample
size and the thorough phenotyping of a sample of out-
patients with PH of diﬀerent aetiologies, which reﬂects the
spectrum of PH patients currently seen at referral centers
and allowed adjusted analysis for many known prognostic
factors in PH. In addition, the long follow-up has to be men-
tioned as an advantage. The following limitations warrant
discussion: First, PBF was not measured simultaneously
with CO by RHC, but nine months later in median.
Although PBF and CO correlated well, there might be a
relevant change of CO during this time interval due to dis-
ease progression or targeted medication. However, neither
invasively measured hemodynamics at diagnosis nor PBF
during follow-up were associated with survival in the present
study. Second, the data derive from a single center, which
may have created bias. However, this ensured a homoge-
neous exploration of patients in a well-experienced PH
center, and all RHCs were done by the same physician,
which minimizes interobserver variability.
In summary, our ﬁndings show that DLCO is strongly and
independently associated with survival in a large sample of
patients with PH of diﬀerent aetiologies. Therefore, DLCO
should be considered in the risk assessment of patients with
PH and evaluated regarding its potential as therapeutic target.
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